Nymox Pharmaceutical Corp (NYMXF)

[bbetts]

HASBROUCK HEIGHTS, N.J., July 21, 2010 (GLOBE NEWSWIRE) -- Singular Research
has initiated coverage of Nymox Pharmaceutical Corporation (Nasdaq:NYMX) with
a "Buy" rating and a 12 month target price of $11.00. The report was written
by Gregory P. Garner, CFA, an equity research analyst for Singular Research.
According to the report, "Nymox Pharmaceutical is a pharmaceutical development
company with a very promising compound for enlarged prostate that is in Phase
3 clinical trials…several anticipated events in the coming 12 to 18 months
will lead to greater investor awareness of the product and push valuations
upwards, in our opinion."


this off bloomberg.....